Search This Blog

Sunday, March 10, 2024

Incyte Data from Phase 2 in Hidradenitis Suppurativa

 

  • Randomized Phase 2 study met the primary endpoint in patents with hidradenitis suppurativa (HS), reinforcing efficacy and safety profile of ruxolitinib cream
  • Results presented as a late-breaking oral presentation at the American Academy of Dermatology (AAD) Annual Meeting
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)